Relay Therapeutics is a Cambridge, Massachusetts clinical-stage precision medicines company (NASDAQ: RLAY) using protein motion to drug historically intractable oncology and genetic-disease targets.

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with difficult-to-treat diseases, beginning with cancers.

Escient Pharmaceuticals is a San Diego, California clinical-stage biopharmaceutical company developing first-in-class, oral small-molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory axis.

Engrail Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 and focused on precision neuroscience. The company develops innovative, precision-targeted small-molecule therapeutics aimed at the molecular mechanisms and neural circuits underlying nervous system disorders, combining internal discovery with strategic…

Pathios Therapeutics is a clinical-stage oncology and immunology drug discovery and development company based in Oxfordshire, United Kingdom, founded in 2017. The company develops small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to counteract the immunosuppressive tumor microenvironment; its lead asset PTT-4256 is a…

Basking Biosciences is a clinical-stage biopharmaceutical company in Research Triangle, North Carolina (with operations in Mitchelton, Queensland, Australia) developing novel therapies for life-threatening blood clots.

Areteia Therapeutics was a clinical-stage biotechnology company, formerly based in Chapel Hill, North Carolina, operating in the life-sciences sector. As of the July 2026 enrichment pass the company is no longer operating: areteiatx.com serves only a closure notice directing asset and general inquiries to contact addresses, and the company…

Semnur Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing non-opioid pain-management therapies. Its lead program, SP-102 (SEMDEXA), is a novel, non-opioid, preservative-free and particulate-free injectable corticosteroid gel formulation intended to treat moderate-to-severe chronic radicular pain (sciatica).

Braveheart Bio is a late clinical-stage biopharmaceutical company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiac conditions. Its lead candidate, BHB-1893, is a selective cardiac myosin inhibitor (licensed as HRS-1893 from Hengrui Pharma) designed to reduce excessive heart-muscle contraction and improve…

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that spun out of the University of British Columbia and BC Cancer in 2019 to develop a portfolio of targeted cancer therapies.

Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapies designed to guide and reprogram T cells to overcome autoimmunity, inflammatory disease, chronic viral infection, and cancer.

Grey Wolf Therapeutics (Greywolf Therapeutics) is a clinical-stage biotechnology company developing a new therapeutic class of immunotherapies through antigen modulation, aimed at treating people living with cancers and autoimmune disorders.

Chimerix, Inc. was a biopharmaceutical company headquartered in Durham, North Carolina, focused on developing medicines for serious and life-threatening diseases. It is best known for brincidofovir (TEMBEXA), an antiviral approved by the U.S.

Rallybio Corporation (NASDAQ RLYB) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, founded in 2018, developing and commercializing life-transforming therapies for patients with severe and rare diseases.

Apreohealth — Apreo Health is a clinical-stage medical device company based in Menlo Park, California, developing a novel, tissue-sparing bronchoscopic treatment for severe emphysema.

Erasca is a clinical-stage precision oncology company (NASDAQ: ERAS) headquartered in San Diego, California, whose name is its mission: to erase cancer. The company is singularly focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company headquartered in Dublin, Ireland, focused on developing novel anti-infective medications to treat multi-drug resistant (MDR) bacterial infections.

Oblenio Bio is a clinical-stage biotechnology company developing tri-specific antibody immunotherapies for refractory autoimmune diseases. Its lead candidate, LBL-051, is a tri-specific T-cell engager targeting BCMA, CD19, and CD3 to deplete B-cells and pursue long-term, drug-free remission and immune reset for patients.

MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for endocrine and metabolic disorders, built on its proprietary PEPs platform. Lead programs include canvuparatide (MBX 2109) for hypoparathyroidism, plus MBX 4291, MBX 5765, and MBX 6XXX.

Affinia Therapeutics is a clinical-stage biotechnology company in Waltham, Massachusetts pioneering next-generation adeno-associated virus (AAV) gene therapies. Using AI and structural modeling to rationally design novel capsids that better target tissues for improved safety and effectiveness, Affinia develops therapeutic cargoes for devastating…